牛唐2021-03-31 09:44
$灿菲特生物制药(CANF)$ 的药物Piclidenoson和Namodenoson在现有的六份分销协议中,剩余的潜在里程碑付款高达约1.3亿美元,外加两位数的净销售额分成。$新泰医药(MDGL)$ $泰格医药(SZ300347)$查看全文
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-08-31 AccNo: 0001213900-18-011964 Size: 1 MB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-08-21 AccNo: 0001213900-18-011493 Size: 22 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ F-1 - Registration statement for certain foreign private issuers Filed: 2018-08-08 AccNo: 0001213900-18-010490 Size: 605 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ F-1 - Registration statement for certain foreign private issuers Filed: 2018-08-08 AccNo: 0001213900-18-010490 Size: 605 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-08-08 AccNo: 0001213900-18-010486 Size: 4 MB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-08-08 AccNo: 0001213900-18-010486 Size: 4 MB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-08-07 AccNo: 0001213900-18-010336 Size: 35 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-08-07 AccNo: 0001213900-18-010336 Size: 35 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-08-06 AccNo: 0001213900-18-010213 Size: 27 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-07-17 AccNo: 0001213900-18-009271 Size: 31 KB 网页链接